[The clinical significance of copeptin and matrix metalloproteinases in men with acute coronary syndrome].
To evaluate clinical value copeptin and matrix metalloproteinases in men with acute coronary syndrome (ACS). The study included 152 men with ACS. After evaluation of the traditional markers of myocardial damage, the patients were divided into 2 groups: the first group included patients with myocardial infarction (MI) - 84 people, the average age was 56.6±1.0 years, the second - with unstable angina (UA) - 68 at the age of 61,4±1.2 years. All patients at admission and after 6 hours and on day 6 of hospitalization were evaluated for the level of CPK MB, troponin I, copeptin, MMP-1, MMP-2, MMP-7, MMP-9 and TIMP-1. Concentration of copeptin at admission in patients with it is 3.5 times higher than in the group with UA and significantly higher than that of control group. To 6‑th day of hospitalization, the concentration of copeptin reduced, but nonetheless remains significantly higher than in the control group (0,9±0,1 vs. 0.2±0,0, p=0.000) without significant differences with group UA. The level of MMP-1 and MMP-2 in patients with MI and UA at admission higher than in the control group, and in case of MI these levels are significantly higher than in case of UA. The obtained data indicates the possibility of using copeptin as a marker of myocardial damage. Additionally, it indicates myocardial damage an increase in the level of MMP-1, MMP-2 and MMP-7.